Pfizer's stock rallies after drug giant cites strength in its COVID-19 drugs and Vyndaqel heart medication Pfizer Inc.'s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit ...

Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales growth that’s driving its battle for the obesity startup Metsera. The drugmaker ...

(Reuters) -Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday. CEO ...

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs ...

Pfizer's third-quarter sales fell 6% year over year to $16.65 billion, beating the consensus of $16.59 billion. The revenue reflected an operational decline of 7%. The operational decrease was ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate on the heels of a 10% jump in second-quarter revenue on strength in its Vyndaqel heart medication ...

Quarterly sales, profit come in above Wall Street estimates New profit forecast includes one-time deal charge, some tariff costs Sales of COVID products surpass analysts' expectations Aug 5 (Reuters) ...